FDA advisory committee recommends Novartis’ CTL019 for r/r B-cell ALL
The CTL019 is an investigational chimeric antigen receptor T cell (CAR-T) therapy developed to treat patients with r/r B-cell ALL. The recommendation of ODAC was based on the
Germany-based Merck KGaA (Merck) has completed its previously announced acquisition of the chromatography business of JSR Life Sciences.